251 related articles for article (PubMed ID: 25868389)
1. Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis.
Chitikova Z; Pusztaszeri M; Makhlouf AM; Berczy M; Delucinge-Vivier C; Triponez F; Meyer P; Philippe J; Dibner C
Oncotarget; 2015 May; 6(13):10978-93. PubMed ID: 25868389
[TBL] [Abstract][Full Text] [Related]
2. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
3. Generation of a Potential Prognostic Matrix for Papillary Thyroid Cancer that Assesses Age, Tumor Size, Transforming Growth Factor-β, and BRAFV600E Mutation.
Wang P; Lun Y; Fu Y; Wang F; Zhao S; Wang Y; Hou X
Oncol Res Treat; 2017; 40(10):586-592. PubMed ID: 28892804
[TBL] [Abstract][Full Text] [Related]
4. [BRAF initiating mutations in the papillary thyroid carcinoma].
Rusinek D; Gubała E
Endokrynol Pol; 2006; 57(4):438-44. PubMed ID: 17006850
[TBL] [Abstract][Full Text] [Related]
5. Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.
Makhlouf AM; Chitikova Z; Pusztaszeri M; Berczy M; Delucinge-Vivier C; Triponez F; Meyer P; Philippe J; Dibner C
Oncotarget; 2016 Jul; 7(29):45776-45788. PubMed ID: 27329729
[TBL] [Abstract][Full Text] [Related]
6. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
7. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.
Finley DJ; Arora N; Zhu B; Gallagher L; Fahey TJ
J Clin Endocrinol Metab; 2004 Jul; 89(7):3214-23. PubMed ID: 15240595
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
11. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology.
Moon HJ; Kwak JY; Kim EK; Choi JR; Hong SW; Kim MJ; Son EJ
Ann Surg Oncol; 2009 Nov; 16(11):3125-31. PubMed ID: 19644722
[TBL] [Abstract][Full Text] [Related]
12. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma.
Hawthorn L; Stein L; Varma R; Wiseman S; Loree T; Tan D
Head Neck; 2004 Dec; 26(12):1069-83. PubMed ID: 15515157
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
[TBL] [Abstract][Full Text] [Related]
14. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
15. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
16. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
[TBL] [Abstract][Full Text] [Related]
19. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
[TBL] [Abstract][Full Text] [Related]
20. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]